BRAF and neoplasm: Altogether, in vitro results and in vivo subcutaneous experiments confirmed that BRAFV600E PMP tumors are very addicted to BRAF mutation and encorafenib alone was sufficient to exert a potent reduction of cancer cell viability and tumor growth.